Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Shares and Warrants (Tables)

Common Shares and Warrants (Tables)

9 Months Ended

May 31, 2020

Equity [Abstract]

Schedule of option and warrant exercises

Type of Issuance			Number of				Total
			Shares				Value $
Option exercise			110,000				11,000
Private placement⁽¹⁾			10,689,956				2,859,914
			10,799,956			$	2,870,914

⁽¹⁾ Total fees of $156,288 were paid for total net receipt of $2,703,626.

Schedule of warrant

		Number of Warrants				Weighted Average Exercise Price $
Balance August 31, 2018			3,286,274				0.72
Cancelled/expired			(17,498	)			0.59
Exercised			(1,626,513	)			0.49
Issued			1,183,062				1.99
Balance August 31, 2019			2,825,325				1.38
Cancelled/expired			(750,000	)			1.50
Issued			12,072,829				0.42
Balance May 31, 2020			14,148,154				0.56

Schedule of warrants granted as compensation warrants by using the Black-Scholes option pricing model

		May 31 2020
Expected volatility			91% - 94%
Risk-free interest rate			0.36% - 2.87%
Expected life			2 - 5 years
Dividend yield			0%
Estimated fair value per warrant			0.28 - 0.54

Schedule of warrants outstanding

# of Warrants			Weighted Average Remaining Contractual Life		Weighted Average Exercise Price $
975,325			0.42 years			2.25
100,000			0.98 years			0.96
250,000			0.98 years			1.55
750,000			1.36 years			0.14
225,000			2.43 years			0.80
1,562,995			1.45 years			0.80
269,500			1.50 years			0.80
500,000			4.79 years			0.30
8,028,254			4.93 years			0.35
1,487,080			4.95 years			0.35
14,148,154			3.84 years			0.56